Gryphon Bio, Inc.
Gryphon Bio is a clinical stage company focused on developing novel blood tests for brain health, leveraging over 20 years of -omic research to identify brain-specific biomarkers in the blood. Their mission is to improve patient lives through innovative diagnostics for various CNS diseases.
Industries
Nr. of Employees
small (1-50)
Gryphon Bio, Inc.
South San Francisco, California, United States, North America
Products
Blood-based diagnostic tests for brain health
Diagnostic tests under development that measure brain-derived molecular signatures in blood to detect, monitor, and inform clinical decisions for CNS conditions.
Blood-based diagnostic tests for brain health
Diagnostic tests under development that measure brain-derived molecular signatures in blood to detect, monitor, and inform clinical decisions for CNS conditions.
Services
Clinical study execution for blood-based diagnostics
Designing and running clinical studies with patient biosampling to evaluate and refine blood tests for early detection and monitoring of brain conditions.
Biomarker discovery and assay development
R&D services to discover blood-based biomarkers using multi-omics and proteomics, and to develop analytical assays with amplification-based detection where appropriate.
Companion diagnostic and clinical trial enrichment support
Use of blood-based biomarkers to enrich trial cohorts, monitor response, and de-risk drug development workflows.
Preclinical and translational research services
Preclinical model studies and integration of neuroimaging with molecular analyses to characterize mechanisms and temporal biomarker dynamics.
Regulatory strategy and grant-supported program leadership
Support for regulatory engagement, grant-funded program management, and generation of evidence packages to advance biomarker-based diagnostics.
Clinical study execution for blood-based diagnostics
Designing and running clinical studies with patient biosampling to evaluate and refine blood tests for early detection and monitoring of brain conditions.
Biomarker discovery and assay development
R&D services to discover blood-based biomarkers using multi-omics and proteomics, and to develop analytical assays with amplification-based detection where appropriate.
Companion diagnostic and clinical trial enrichment support
Use of blood-based biomarkers to enrich trial cohorts, monitor response, and de-risk drug development workflows.
Preclinical and translational research services
Preclinical model studies and integration of neuroimaging with molecular analyses to characterize mechanisms and temporal biomarker dynamics.
Regulatory strategy and grant-supported program leadership
Support for regulatory engagement, grant-funded program management, and generation of evidence packages to advance biomarker-based diagnostics.
Expertise Areas
- Blood-based biomarker discovery
- Neuroproteomics and proteomic biomarker analysis
- Multi-omics data integration and bioinformatics
- Diagnostic assay development and validation
Key Technologies
- Proteomics
- Multi-omics
- Bioinformatics / large-scale molecular analytics
- Amplification-based molecular detection